Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase 2

• Conditions: Breast Neoplasms
• Interventions: Drug: aspirin; Drug: Exemestane

• Registration Number: NCT01431053
• Lead Sponsor: Chinese Academy of Medical Sciences

Brief Summary

This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-07
• Study First Submitted: 2011-09-07
• Study First Submitted QC: 2011-09-08
• Study First Posted: 2011-09-09
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-12
• Last Update Posted: 2013-03-13
• Primary Completion: 2014-07
• Study Completion: 2014-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 160

Inclusion Criteria

• Breast cancer after surgery postmenopausal

Exclusion Criteria

• contraindication of aspirin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Exemestane + Aspirin	aspirin	-
Exemestane + Aspirin	Exemestane	-
Exemestane	Exemestane	-

Primary Outcome Measures

Name	Time	Method
Quality of Life	4 years

Trial Locations

Locations (1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China